Nearly a decade has passed since we first began our audit of clinical outcomes using multiple subcutaneous injections of the lipodissolve agent Lipostabil N (Sanofi-Aventis, Frankfurt, Germany) to reduce adipose deposits in the abdomen and other areas.1 That lipodissolve agent contained phosphatidylcholine (PC) and deoxycholate (DC) as active ingredients. These derivatives of soya bean and bile extracts respectively had regulatory approval for certain applications, but neither had been formally approved for subcutaneous injection. However, this mixture gained early support as an off-label, minimally invasive alternative to traditional lipoplasty techniques.2 By 2006, regulatory agencies such as the US Food and Drug Administration (FDA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) had restricted the import of Lipostabil N for …